Table 1. Characteristics of the study population (n=12,125).
| Characteristics | No. (%) | |
|---|---|---|
| Age (yr) | ||
| ≤ 50 | 6,826 (56.3) | |
| > 50 | 5,298 (43.7) | |
| Sex | ||
| Female | 12,040 (99.3) | |
| Male | 41 (0.3) | |
| Unknown | 44 (0.4) | |
| T stage | ||
| T0 | 286 (2.4) | |
| Tis | 1,759 (14.5) | |
| T1 | 6,201 (51.1) | |
| T2 | 3,414 (28.2) | |
| T3 | 343 (2.8) | |
| T4 | 122 (1.0) | |
| N stage | ||
| N0 | 8,523 (70.3) | |
| N1 | 2,222 (18.2) | |
| N2 | 830 (6.9) | |
| N3 | 533 (4.4) | |
| Unknown | 17 (0.1) | |
| M stage | ||
| M0 | 12,020 (99.1) | |
| M1 | 105 (0.9) | |
| ER | ||
| Negative | 3,462 (28.5) | |
| Positive | 7,458 (61.5) | |
| Unknown | 1,205 (10.0) | |
| PR | ||
| Negative | 4,982 (41.1) | |
| Positive | 5,865 (48.4) | |
| Unknown | 1,278 (10.5) | |
| HER2 | ||
| Negative | 6,299 (52.0) | |
| Positive | 2,077 (17.1) | |
| Unknown | 3,749 (30.9) | |
| Grade | ||
| G1 | 2,103 (17.3) | |
| G2 | 4,425 (36.5) | |
| G3 | 2,116 (17.3) | |
| Unknown | 3,481 (28.7) | |
| NCT | ||
| No | 10,556 (87.1) | |
| Yes | 1,569 (12.9) | |
ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; NCT = neoadjuvant chemotherapy.